Evidence map›Paper›PMID 34660806›Full record

ArticleBioMed research international2021

Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.

Zuyi Ma, Zhenchong Li, Zuguang Ma, Zixuan Zhou, Hongkai Zhuang, Chunsheng Liu, Bowen Huang, Yiping Zou, Zehao Zheng, LinLing Yang and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Deciphering of SOX9 Functions in Pancreatic Cancer Cells.International journal of molecular sciences · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Zuyi MaShantou University of Medical College, Shantou 515000, China.ORCID https://orcid.org/0000-0002-8517-7600
Zhenchong LiDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Zuguang MaSanshui Disease Prevention Cure Station, Foshan 528100, China.
Zixuan ZhouDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Hongkai ZhuangShantou University of Medical College, Shantou 515000, China.
Chunsheng LiuShantou University of Medical College, Shantou 515000, China.
Bowen HuangDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Yiping ZouShantou University of Medical College, Shantou 515000, China.
Zehao ZhengShantou University of Medical College, Shantou 515000, China.
LinLing YangGuangzhou Medical University, Guangzhou 511436, China.
Yuanfeng GongDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Shanzhou HuangDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.ORCID https://orcid.org/0000-0002-7575-5841
Qi ZhouDepartment of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University, Huizhou 516081, China.ORCID https://orcid.org/0000-0002-0480-2110
Chuanzhao ZhangDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.ORCID https://orcid.org/0000-0001-6553-4458
Baohua HouDepartment of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.ORCID https://orcid.org/0000-0002-4239-1367
Guangdong Academy of Medical Sciences · CNShantou University · CNChinese Center For Disease Control and Prevention · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNGuangzhou Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKRAS was reported to affect some metabolic genes and promote metabolic reprogramming in solid tumors. However, there was no comprehensive analysis to explore KRAS-associated metabolic signature or risk model for pancreatic cancer (PC).

methodsIn the current study, multiple bioinformatics analyses were used to identify differentially expressed metabolic genes based on KRAS mutation status in PC. Then, we developed and validated a prognostic risk model based on the selected KRAS-associated metabolic genes. Besides, we explored the association between the risk model and the metabolic characteristics as well as gemcitabine-associated chemoresistance in PC.

results6 KRAS-associated metabolic genes (i.e., CYP2S1, GPX3, FTCD, ENPP2, UGT1A10, and XDH) were selected and enrolled to establish a prognostic risk model. The prognostic model had a high C-index of 0.733 for overall survival (OS) in TCGA pancreatic cancer database. The area under the curve (AUC) values of 1- and 3-year survival were both greater than 0.70. Then, the risk model was validated in two GEO datasets and also presented a satisfactory discrimination and calibration performance. Further, we found that the expression of some KRAS-driven glycolysis-associated genes (PKM, GLUT1, HK2, and LDHA) and gemcitabine-associated chemoresistance genes (i.e., CDA and RMM2) was significantly upregulated in high-risk PC patients evaluated by the risk model.

conclusionsWe constructed a risk model based on 6 KRAS-associated metabolic genes, which predicted patients' survival with high accuracy and reflected tumor metabolic characteristics and gemcitabine-associated chemoresistance in PC.

Indexed as

Models, BiologicalCell Line, TumorDeoxycytidineDrug Resistance, NeoplasmGemcitabineGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMutationPancreatic NeoplasmsPhenotypePrognosisProto-Oncogene Proteins p21(ras)Reproducibility of ResultsRisk FactorsROC CurveDeoxycytidineGemcitabineKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID34660806
PMCPMC8516536
OpenAlexW3100043216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.